MARAVAI LIFESCIENCES HOLDINGS, INC.

Maravai LifeSciences Holdings provides products and services that support the development of drug therapies, vaccines, and diagnostics, as well as human disease research. The business operates through two primary segments: TriLink and Cygnus. The TriLink segment supplies modified nucleic acids and associated technologies, including messenger RNA, CleanCap capping reagents, ModTail modifications, oligonucleotides, nucleoside triphosphates, specialty enzymes, and contract synthesis services. The Cygnus segment focuses on biologics safety testing solutions, offering host cell protein detection kits, viral clearance prediction assays, auxiliary reagents, and custom analytical testing. Its client base spans biopharmaceutical corporations, emerging biotechnology enterprises, academic and life science research institutions, and diagnostic organizations.

As of late 2025, the enterprise employs 435 full-time personnel globally. It serves clients across roughly 60 nations outside the United States using direct sales teams and distributor partners. Operational sites supporting manufacturing, analysis, and distribution are situated in San Diego, California; Leland, North Carolina; Sterling, Virginia; and Jupiter, Florida. The provided text does not state a corporate headquarters.

Summary of the business section of Maravai Lifesciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 435 full-time employees globally.”